External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy.

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/42709068

Christian Hoffmann; Daniel Groener; Felix K H Chun; Manuel Ritter; Markus Essler; Mike Wenzel; Milka Marinova; Paul Schmitt; Philipp Krausewitz; Philipp Mandel; Thomas Büttner

Sep 9, 2026